MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

Chiara Perfumo, Stefano Parodi, Katia Mazzocco, Raffaella Defferrari, Alberto Inga, Giovanna Bianchi Scarrà, Paola Ghiorzo, Riccardo Haupt, Gian Paolo Tonini, Gilberto Fronza

Research output: Contribution to journalArticle

Abstract

Background. MDM2 is a major negative regulator of p53 function and is directly regulated by MYCN in neuroblastoma (NB) cells. MDM2 SNP309, a T-to-G substitution in the MDM2 promoter associated with higher gene expression compared to wild-type, may attenuate the p53 pathway in NB, in which p53 mutations are rare. We investigated its impact on NB development and survival in relation with major clinical and biological characteristics. Procedure. A consecutive cohort of 497 NB children, diagnosed in Italy between 1995 and 2005, and a healthy control population of 471 adults were genotyped for MDM2 SNP309. NB patients were followed up until June 30, 2008. Results. Patients and controls showed similar distribution of MDM2 SNP309 genotypes. In patients, the polymorphism was not associated with any characteristic at diagnosis. In localized stages no effect of the polymorphism on survival was evident. In stage 4 patients overall survival (OS), event free survival (EFS) and survival after relapse (SAR) were significantly poorer for TG/GG than for TT patients (P=0.008; P=0.013; P=0.046, respectively). In this group, such an effect was more evident in patients with MYCN amplification (OS: P

Original languageEnglish
Pages (from-to)576-583
Number of pages8
JournalPediatric Blood and Cancer
Volume53
Issue number4
DOIs
Publication statusPublished - Oct 2009

    Fingerprint

Keywords

  • MDM2
  • Neuroblastoma
  • Polymorphism
  • Progression
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this